Page 1

Agile THERAPEUTICS Agile Therapeutics Reports Third Quarter 2021 Financial Results November 2 , 2021 Prescription Demand Growth Continues in the Third Quarter 2021 with a 61 % Increase in Twirla Cycles Dispensed Twirla Refill Rates Continue to Grow by 86 % in Third Quarter 2021 Company Advances Programs Focused on Increasing Demand for Twirla Management to Host Conference Call Today , Tuesday , November 2 , 2021 at 4:30 p.m. EDT PRINCETON , N.J. , Nov. 02 , 2021 ( GLOBE NEWSWIRE ) -- Agile Therapeutics , Inc. ( Nasdaq : AGRX ) , a women's healthcare company , today reported financial results for the three months ended September 30 , 2021 and provided a corporate update . " We are encouraged by solid double - digit growth in prescription demand as measured by cycles dispensed . We are excited that the quarterly prescription growth came from both new prescriptions and refills , " said Chairman and Chief Executive Officer Al Altomari . " Our goal is to continue to accelerate growth for the Twirla brand and reduce our time to profitability . We believe we have the awareness and access programs in place to execute on our plans and intend to make meaningful investments in marketing to help increase demand . " Recent Corporate Developments and Third Quarter 2021 Results : Twirla Performance and Updates • During the third quarter 2021 , total cycles dispensed were 9,747 , representing an increase of 61 % from the end of the second quarter . Total prescriptions in the third quarter 2021 were 7,374 , representing an increase of 47 % from the end of the second quarter . New prescriptions were 3,584 and grew by 25 % over the same period . Prescription growth was driven by an increase in the number of prescribers , which as of September 30 , 2021 was approximately 3,394 healthcare providers ( HCPs ) , and growing refill rates . As of September 30 , 2021 , 3,790 prescriptions dispensed at pharmacies were refills , which represented an increase of 86 % during the third quarter . The Company also saw an increase in the number of total prescriptions by prescriber . • In the third quarter 2021 , the Company announced a partnership with Pandia Health , a telehealth service provider , which is now active . Pandia offers an additional point of access for Twirla in a fast - growing channel and represents the first telehealth alliance for Agile and Twirla . • Medi - Cal , the California Medicaid program , placed Twirla on the preferred drug formulary list effective October 1 , 2021 . This secured a preferred position for Twirla on the formulary for Medi - Cal and related programs which provide health care to approximately 15 million beneficiaries . This is significant for Twirla because Medi - Cal is the largest Medicaid program in the U.S. , and the Company believes roughly one - third of the existing contraceptive patch market comes from Medicaid . • The Company recently activated a branded influencer program on Instagram to increase awareness of Twirla as a birth control option and encourage women in the target market to engage in open conversation about the product . • Additionally , the Company announced that Twirla is the first prescription birth control brand to launch podcast advertisements on Spotify . Twirla is also the first birth control brand to run custom content across BuzzFeed , leveraging their social handles across Facebook , Instagram , and Snapchat . • On October 7 , the Company appointed Josephine Torrente as a Class II director to the Company's Board of Directors . Ms. Torrente is a regulatory strategist with extensive experience guiding new drug therapies through the FDA approval process . She also has extensive experience helping companies and investors evaluate pipelines and acquisitions . The Company believes her combined experience will contribute to its efforts to grow as a commercial company . Third Quarter 2021 Financial Results • Net revenue : The Company delivered $ 1.3 million in net product sales revenue in the third quarter .